Thermo Fisher Scientific (TMO) Other Accumulated Expenses (2009 - 2026)

Thermo Fisher Scientific has reported Other Accumulated Expenses for 18 years, with the latest figure at $3.8 billion in Q2 2026.

• Other Accumulated Expenses for Q2 2026 came in at $3.8 billion, up 19.47% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.8 billion (up 19.47% YoY), and the FY2025 annual result was $3.3 billion, up 4.06% from the prior year.
• Other Accumulated Expenses climbed to $3.8 billion in Q2 2026, from $3.7 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $3.8 billion in Q2 2026 and troughed at $2.8 billion in Q3 2023.
• A 5-year average of $3.2 billion and a median of $3.2 billion in 2024 frame the typical range for Other Accumulated Expenses.
• The widest annual swing landed in 2022, when Other Accumulated Expenses jumped 58.89%; it then retreated 11.17% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $3.4 billion in 2022, then fell by 3.22% to $3.2 billion in 2023, then retreated by 1.45% to $3.2 billion in 2024, then increased by 4.06% to $3.3 billion in 2025, then advanced by 14.84% to $3.8 billion in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $3.8 billion in Q2 2026, $3.7 billion in Q1 2026, and $3.3 billion in Q4 2025.